Projects per year
Fingerprint
Dive into the research topics where Jaime R Merchan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 4 Finished
-
-
-
Biomarkers for VEGF and mTOR Blockade in Advanced Renal Cancer
9/19/06 → 8/31/09
Project: Research project
-
Biomarkers for VEGF and mTOR Blockade in Advanced Renal Cancer
9/19/06 → 8/31/09
Project: Research project
-
Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin
Curran, C., Adib, E., Kazakova, V., Grivas, P., Diamantopoulos, L. N., Alva, A. S., Su, C., Jain, R. K., Tandon, A., Necchi, A., Marandino, L., Plastini, T. M., Merchan, J. R. & Sonpavde, G., Feb 2022, In: Clinical Genitourinary Cancer. 20, 1, p. 11-16 6 p.Research output: Contribution to journal › Article › peer-review
-
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors
Azaro, A., Massard, C., Tap, W. D., Cassier, P. A., Merchan, J., Italiano, A., Anderson, B., Yuen, E., Yu, D., Oakley, G., Benhadji, K. A. & Pant, S., Aug 2021, In: Investigational New Drugs. 39, 4, p. 1089-1098 10 p.Research output: Contribution to journal › Article › peer-review
9 Scopus citations -
Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis (Nature Medicine, (2021), 27, 5, (802-805), 10.1038/s41591-021-01324-7)
Choueiri, T. K., Bauer, T. M., Papadopoulos, K. P., Plimack, E. R., Merchan, J. R., McDermott, D. F., Michaelson, M. D., Appleman, L. J., Thamake, S., Perini, R. F., Zojwalla, N. J. & Jonasch, E., Oct 2021, In: Nature medicine. 27, 10, p. 1849 1 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Choueiri, T. K., Bauer, T. M., Papadopoulos, K. P., Plimack, E. R., Merchan, J. R., McDermott, D. F., Michaelson, M. D., Appleman, L. J., Thamake, S., Perini, R. F., Zojwalla, N. J. & Jonasch, E., May 2021, In: Nature medicine. 27, 5, p. 802-805 4 p.Research output: Contribution to journal › Article › peer-review
44 Scopus citations -
Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma
Motzer, R., Alekseev, B., Rha, S. Y., Porta, C., Eto, M., Powles, T., Grünwald, V., Hutson, T. E., Kopyltsov, E., Méndez-Vidal, M. J., Kozlov, V., Alyasova, A., Hong, S. H., Kapoor, A., Gordoa, T. A., Merchan, J. R., Winquist, E., Maroto, P., Goh, J. C., Kim, M. & 18 others, , Apr 8 2021, In: New England Journal of Medicine. 384, 14, p. 1289-1300 12 p.Research output: Contribution to journal › Article › peer-review
Open Access270 Scopus citations